|
|
| Line 1: |
Line 1: |
| | | #REDIRECT [[Procainamide#Use in Specific Populations]] |
| __NOTOC__
| |
| {{Procainamide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| | |
| | |
| ===Teratogenic Effects: Pregnancy Category C===
| |
| | |
| Animal reproduction studies have not been conducted with PA. It also is not known whether PA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. PA should be given to a pregnant woman only if clearly needed.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| Both PA and NAPA are excreted in human milk, absorbed by the nursing infant. Because of the potential for serious adverse reactions in nursing infants, a decision to discontinue nursing or the drug should be made, taking into account the importance of the drug to the mother.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PROCAINAMIDE HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704 | publisher = | date = | accessdate = 11 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Antiarrhythmic agents}}
| |
| | |
| [[Category:Benzamides]]
| |
| [[Category:Anilines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |